These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The association of periprocedural hypertension and adverse outcomes in patients undergoing catheter-directed thrombolysis. Agle SC; McNally MM; Powell CS; Bogey WM; Parker FM; Stoner MC Ann Vasc Surg; 2010 Jul; 24(5):609-14. PubMed ID: 20413257 [TBL] [Abstract][Full Text] [Related]
5. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. Kim HS; Preece SR; Black JH; Pham LD; Streiff MB J Vasc Surg; 2008 Feb; 47(2):388-94. PubMed ID: 18241762 [TBL] [Abstract][Full Text] [Related]
6. Thrombolysis of acute peripheral arterial and venous occlusions with tenecteplase and eptifibatide: a pilot study. Burkart DJ; Borsa JJ; Anthony JP; Thurlo SR J Vasc Interv Radiol; 2003 Jun; 14(6):729-33. PubMed ID: 12817039 [TBL] [Abstract][Full Text] [Related]
7. Fibrinogen and catheter-directed thrombolysis. Ross RL; Beck AW Semin Vasc Surg; 2014 Dec; 27(3-4):182-95. PubMed ID: 26073829 [TBL] [Abstract][Full Text] [Related]
8. Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase I results. Marder VJ; Comerota AJ; Shlansky-Goldberg RD; Davis JP; Deng C; Hanna K; Fineberg D J Thromb Haemost; 2012 Jun; 10(6):985-91. PubMed ID: 22487025 [TBL] [Abstract][Full Text] [Related]
9. Endovascular venous thrombolysis in children younger than 24 months. Kukreja KU; Lungren MP; Patel MN; Johnson ND; Racadio JM; Dandoy C; Tarango C J Vasc Interv Radiol; 2014 Aug; 25(8):1158-64. PubMed ID: 24909354 [TBL] [Abstract][Full Text] [Related]
11. Increased risk of renal dysfunction with percutaneous mechanical thrombectomy compared with catheter-directed thrombolysis. Morrow KL; Kim AH; Plato SA; Shevitz AJ; Goldstone J; Baele H; Kashyap VS J Vasc Surg; 2017 May; 65(5):1460-1466. PubMed ID: 27876521 [TBL] [Abstract][Full Text] [Related]
12. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. Gupta AA; Leaker M; Andrew M; Massicotte P; Liu L; Benson LN; McCrindle BW J Pediatr; 2001 Nov; 139(5):682-8. PubMed ID: 11713447 [TBL] [Abstract][Full Text] [Related]
13. Low dose tissue plasminogen activator treatment for vascular thrombosis following cardiac catheterization in children: a single center experience. Bratincsák A; Moore JW; El-Said HG Catheter Cardiovasc Interv; 2013 Nov; 82(5):782-5. PubMed ID: 22718305 [TBL] [Abstract][Full Text] [Related]
14. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. Ouriel K; Gray B; Clair DG; Olin J J Vasc Interv Radiol; 2000 Mar; 11(3):295-8. PubMed ID: 10735422 [TBL] [Abstract][Full Text] [Related]
15. Plasma Fibrinogen Change as a Predictor of Major Bleeding During Catheter-Directed Thrombolysis. Dorey T; Kong D; Lobo W; Hanlon E; Abramowitz S; Turcotte J; Jeyabalan G Ann Vasc Surg; 2024 Feb; 99():262-271. PubMed ID: 37802144 [TBL] [Abstract][Full Text] [Related]